Effective polyclonal antibodies against the virulence-associated protein D (VapD) of Helicobacter pylori, obtained from recombinant VapD
Fig 5
Production and testing of polyclonal antibodies against rVapD.
A. Representation of the immunization schedule. B. Absorbance values of the indirect ELISA with serum tested at 30, 45 and 60 days (gray arrows in A), rVapD was used at a final concentration of 100 ng. C. Dot blotting test of the final bleeding (red arrow in A) using three dilutions of the serum (1:500, 1:1,000, and 1:2,000) and a serially two-fold diluted concentration of rVapD (1 to 0.03 µg). D. Western blotting of the serum at a dilution of 1:2,000 against a serially two-fold diluted concentration of rVapD (1 to 0.12 µg). Fig 5A was created in BioRender (https://BioRender.com).